Epidemiology, clinical characteristics, and outcome of candidemia: Experience in a tertiary referral center in the UK

International Journal of Infectious Diseases

Volumn 15, Issue 11, 2011, Pages

  Das, I ^a   Nightingale, P ^b   Patel, M ^a   Jumaa, P ^a  

^a UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

^b WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

Author keywords

Advanced age; Candida glabrata; Candidemia; Epidemiology; Mortality; Septic shock

Indexed keywords

ANTIBIOTIC AGENT;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; ANTIBIOTIC THERAPY; ARTICLE; CANDIDA; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA KRUSEI; CANDIDA NORVEGENSIS; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; CANDIDEMIA; CLAVISPORA LUSITANIAE; DISEASE PREDISPOSITION; FEMALE; HUMAN; INCIDENCE; INFECTION RATE; INTENSIVE CARE; MAJOR CLINICAL STUDY; MALE; MORTALITY; OBSERVATIONAL STUDY; POSTOPERATIVE PERIOD; PROSPECTIVE STUDY; SEPTIC SHOCK; TERTIARY HEALTH CARE; UNITED KINGDOM; VASCULAR ACCESS DEVICE;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTIFUNGAL AGENTS; CANDIDA; CANDIDA ALBICANS; CANDIDEMIA; FEMALE; GREAT BRITAIN; HOSPITALS; HUMANS; INCIDENCE; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; REFERRAL AND CONSULTATION; RISK FACTORS; SHOCK, SEPTIC; YOUNG ADULT;

EID: 80054956305     PISSN: 12019712     EISSN: 18783511     Source Type: Journal    
DOI: 10.1016/j.ijid.2011.06.006     Document Type: Article

References (26)

1. Health Protection Agency. Voluntary surveillance of candidaemia in England, Wales, and Northern Ireland 2007. Health Protection Report 2008; 2(38): Healthcare Acquired Infections. London, UK: HPA; 2008. Available at: (accessed July 2011). http://www.hpa.org.uk/hpr/archives/2008/hpr3808.pdf.
2. Wisplinghoff H., Bischoff T., Tallent S.M., Seifert H., Wenzel R.P., Edmond M.B. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 2004, 39:309-317.
3. Pappas P.G., Rex J.H., Lee J., Hamill R.J., Larsen R.A., Powderly W., et al. A prospective observational study of candidemia: epidemiology, therapy and influence on mortality in hospitalized adult and pediatric patients. Clin Infect Dis 2003, 37:634-643.
4. Asmundsdottir L.R., Erlendsdottir H., Gottfredsson M. Increasing incidence of candidemia: results from a 20-year nationwide study in Iceland. J Clin Microbiol 2002, 40:3489-3492.
5. Beck-Sague C., Jarvis W.R. Secular trends in the epidemiology of nosocomial fungal infections in the United States, 1980-1990: National Nosocomial Infections Surveillance System. J Infect Dis 1993, 167:1247-1251.
6. Edmond M.B., Wallace S.E., McClish D.K., Pfaller M.A., Jones R.N., Wenzel R.P. Nosocomial bloodstream infections in United States hospitals: a three year analysis. Clin Infect Dis 1999, 29:239-244.
7. Leleu G., Aergerter P., Guidet B. Collège des Utilisateurs de Base de Données en Réanimation. Systemic candidiasis in intensive care units: a multicentre, matched-cohort study. J Crit Care 2002, 17:168-175.
8. Pelz R.K., Lipsett P.A., Swoboda S.M., Diener-West M., Powe N.R., Brower R.G., et al. Candida infections: outcome and attributable ICU costs in critically ill patients. J Intensive Care Med 2000, 15:255-261.
9. Zaoutis T.E., Argon J., Chu J., Berlin J., Walsh T., Feudtner C. The epidemiology and attributable outcomes of candidemia in adults and children hospitalized in the United States: a propensity analysis. Clin Infect Dis 2005, 41:1232-1239.
10. Tortorano A., Kibbler C., Peman J., Bernhardt H., Klingspor L., Grillot R. Candidaemia in Europe: epidemiology and resistance. Int J Antimicrob Agents 2006, 27:359-366.
11. Eggimann P., Garbino J., Pittet D. Epidemiology of Candida species infections in critically ill non-immunosuppressed patients. Lancet 2003, 3:685-702.
12. Almirante B., Rodriguez D., Park B.J., Cuenca-Estrella M., Planes A.M., Almela M. Epidemiology and predictors of mortality in cases of Candida bloodstream infection: results from population-based surveillance, Barcelona, Spain, from 2002 to 2003. J Clin Microbiol 2005, 43:1829-1835.
13. Schelenz S., Gransden W.R. Candidaemia in a London teaching hospital: analysis of 128 cases over a 7-year period. Mycoses 2003, 46:390-396.
14. Hassan I., Powell G., Sidhu M., Hart W.M., Denning D.W. Excess mortality, length of stay and cost attributable to candidaemia. J Infect 2009, 59:360-365.
15. Pittet D., Li N., Woolson R.F., Wenzel R.P. Microbiological factors influencing the outcome of nosocomial bloodstream infections: a 6 year validated, population-based model. Clin Infect Dis 1997, 24:1068-1078.
16. Antoniadou A., Torres H., Lewis R., Thornby J., Bodey G.P., Tarrand J.P., et al. Candidemia in a tertiary care cancer center: in vitro susceptibility and its association with outcome of initial antifungal therapy. Medicine (Baltimore) 2003, 82:309-321.
17. Pfaller M.A., Diekema D.J. Twelve years of fluconazole in clinical practice: global trends in species distribution and fluconazole susceptibility of bloodstream isolates of Candida. Clin Microbiol Infect 2004, 10(Suppl 1):11-23. International Fungal Surveillance Participant Group.
18. Edwards J. Candida species. Mandell, Douglas and Bennett's principles and practice of infectious diseases 2005, 2938-2957. Churchill Livingstone, Philadelphia. 6th ed. G.L. Mandell, J.E. Bennett, R. Dolin (Eds.).
19. Falagas M.E., Roussos N., Vardakas K.Z. Relative frequency of albicans and the various non-albicans Candida spp among candidemia isolates from inpatients in various parts of the world: a systematic review. Int J Infect Dis 2010, 14:e954-e966.
20. Kibbler C.C., Seaton S., Barnes R.A., Gransden W.R., Holliman R.E., Johnson E.M., et al. Management and outcome of bloodstream infections due to Candida species in England and Wales. J Hosp Infect 2003, 54:18-24.
21. Odds F.C., Hanson M.F., Davidson A.D., Jacobsen M.D., Wright P., Whyte J.A., et al. One year prospective survey of Candida bloodstream infections in Scotland. J Med Microbiol 2007, 56:1066-1075.
22. Gudlaugsson O., Gillespie S., Lee K., Berg J.V., Hu J., Messer S., et al. Attributable mortality of nosocomial candidemia, revisited. Clin Infect Dis 2003, 37:1172-1177.
23. Weinberger M., Leibovici L., Perez S., Samra Z., Ostfeld I., Levi I., et al. Characteristics of candidaemia with Candida albicans compared with non-albicans Candida species and predictors of mortality. J Hosp Infect 2005, 61:146-154.
24. Malani A., Hmoud J., Chiu L., Carver P., Bielaczyc A., Kauffman C. Candida glabrata fungemia: experience in a tertiary care center. Clin Infect Dis 2005, 41:975-981.
25. Garey K., Rege M., Pai M., Mingo D., Suda K., Turpin R., Bearden D. Time initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study. Clin Infect Dis 2006, 43:25-31.
26. Morrell M., Fraser V., Kollef M. Delaying the empiric treatment of Candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. Antimicrob Agents Chemother 2005, 49:3640-3645.